Journal of the American College of Clinical Pharmacy : JACCP最新文献

{"title":"Comment on “Retrospective cohort study of ambulatory care pharmacist interventions' impact on incidence of therapeutic response in anxiety and depression”","authors":"Angeleki Zecopoulos Pharm.D., B.S., Matthew Joseph Pharm.D., B.S., Lucas A. Berenbrok Pharm.D., M.S.","doi":"10.1002/jac5.70001","DOIUrl":"https://doi.org/10.1002/jac5.70001","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"232"},"PeriodicalIF":1.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining opioid stewardship","authors":"Lucas G. Hill Pharm.D., FCCP","doi":"10.1002/jac5.70002","DOIUrl":"https://doi.org/10.1002/jac5.70002","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"168-170"},"PeriodicalIF":1.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to comment on “Restrospective cohort study of ambulatory care pharmacist interventions' impact on incidence of therapeutic response in anxiety and depression”","authors":"Ashlyn M. Kiebach Pharm.D., Tara E. McAlpine Pharm.D., Mitchell H. Cavanaugh Pharm.D., Jessica A. Benzer Pharm.D.","doi":"10.1002/jac5.70013","DOIUrl":"https://doi.org/10.1002/jac5.70013","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"233"},"PeriodicalIF":1.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists should not be gatekeepers but rather advocates for evidence-based substance use policies","authors":"Stuart T. Haines Pharm.D., FCCP","doi":"10.1002/jac5.70000","DOIUrl":"https://doi.org/10.1002/jac5.70000","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"166-167"},"PeriodicalIF":1.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists in diabetes management: Enhancing patient care through practice, education, and advocacy","authors":"Jennifer N. Clements Pharm.D., FCCP, Christine A. Schumacher Pharm.D., FCCP","doi":"10.1002/jac5.2077","DOIUrl":"https://doi.org/10.1002/jac5.2077","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"74-76"},"PeriodicalIF":1.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous glucose monitor outcomes in Latino populations across multiple federally qualified health centers","authors":"Ana Hernandez-Calderon Pharm.D.,&nbsp;Jasmine Gonzalvo Pharm.D.,&nbsp;Jessica S. Triboletti Pharm.D.,&nbsp;Todd A. Walroth Pharm.D.,&nbsp;Samuel P. Lewis Pharm.D., M.S.,&nbsp;Lauren Pence Pharm.D.","doi":"10.1002/jac5.70007","DOIUrl":"https://doi.org/10.1002/jac5.70007","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Utilization of continuous glucose monitoring (CGM) leads to a greater reduction in hemoglobin A1C (A1C) in individuals with diabetes compared with fingerstick blood glucose monitoring (BGM) alone. CGM also reduces diabetes-related hospitalizations. Evidence shows CGM is underutilized in racial or ethnic minority groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>There is a need to increase CGM access and evaluate the impact in underrepresented populations to prevent health disparities. Eskenazi Health added CGM devices as a covered product on the Eskenazi Health Financial Assistance Program (EH FAP) formulary. CGMs were approved for patients with diabetes taking insulin or a sulfonylurea. The purpose of this study was to assess the clinical impact of improving CGM access following EH FAP coverage with a focus on Latino populations across multiple Federally Qualified Health Centers (FQHCs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective, cohort study of nine FQHCs was conducted for all adults with EH FAP who were dispensed CGMs at Eskenazi Health outpatient pharmacies between June 1, 2022 and December 31, 2023. The primary outcome was A1C pre- and post-CGM use. Secondary outcomes included CGM adherence as characterized by proportion of days covered (PDC). All outcomes were also assessed in predetermined subgroups comparing Pharm.D. versus Primary Care and Endocrinology providers and Latino versus non-Latino individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 184 individuals were included. Median (interquartile range) A1C at baseline was 9.6% (8.1, 11.8). At 3 months, median A1C decreased to 8.4% (<i>n</i> = 96; change of −0.9%; <i>p</i> &lt; 0.001); at 1 month, median A1C decreased to 7.9% (<i>n</i> = 19; change of −1.1%; <i>p</i> = 0.028); and at 6 months, median A1C decreased to 8.4% (<i>n</i> = 55; change of −0.7; <i>p</i> = 0.007). PDC resulted as a median of 100% (77, 100). No difference in A1C outcomes were observed between Pharm.D. versus other prescribers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A1C significantly improved post-CGM use at 1, 3, and 6 months in a population that has historically experienced disparities in diabetes care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"192-197"},"PeriodicalIF":1.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of pharmacist management on chronic obstructive pulmonary disease in a family medicine residency clinic","authors":"Jacqueline Elaine Figueras Pharm.D.,&nbsp;Christina Putnam Pharm.D.,&nbsp;Carolyn Wong Pharm.D.,&nbsp;Sholeh Bagheri M.D.,&nbsp;Marilyn Darr M.D., Pharm.D.,&nbsp;Luke A Vander Weide Pharm.D.","doi":"10.1002/jac5.70006","DOIUrl":"https://doi.org/10.1002/jac5.70006","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Studies support pharmacist intervention to improve adherence and reduce hospital admissions in the management of chronic obstructive pulmonary disease (COPD); however, evidence is lacking to assess pharmacist management on symptom improvement and disease control using COPD Assessment Test (CAT) scores in a primary care setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The purpose of this study was to assess the impact of pharmacist involvement in performing spirometry and therapeutic management of COPD on symptoms and inhaler use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a prospective cohort study of patients with COPD at a family medicine residency clinic from January 2021 to November 2022. Patients included were 18 years of age or older, had a confirmed diagnosis of COPD with spirometry, and completed at least one COPD management visit with the pharmacist. Pharmacists performed spirometry, modified inhaler therapy, provided COPD and inhaler education, reviewed and ordered immunizations and labs, and provided tobacco cessation education and management if applicable. The primary outcome was the change in CAT scores from baseline to 3 months. The secondary outcome was the percentage of patients on guideline-directed inhaler therapy at 3 months compared with baseline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 77 spirometry visits were completed by the pharmacist, with confirmed COPD in 49 patients who were managed by the pharmacist and included in the final analysis. At baseline, the average age was 66 years old, 53% were males, and only 6% had no smoking history. The mean CAT score improved by 5.0 points (<i>p</i> &lt; 0.001) from baseline. At baseline, 45% were on guideline-directed therapy, which increased to 98% at final follow-up (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study assessed the impact of pharmacist-led spirometry and COPD management at a family medicine residency clinic. Based on the results, pharmacist involvement in COPD management resulted in an improvement in symptoms and increased use of guideline-directed inhaler therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"171-181"},"PeriodicalIF":1.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of glycemic outcomes following implementation of a pharmacist-led insulin management service in postoperative cardiothoracic surgery patients","authors":"Sydney Kermeen Pharm.D.,&nbsp;Brittany White Pharm.D.,&nbsp;Alicia Stowe M.S.,&nbsp;Christopher Wilson Pharm.D.","doi":"10.1002/jac5.2079","DOIUrl":"https://doi.org/10.1002/jac5.2079","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Perioperative hyperglycemia is a predictor of mortality in cardiothoracic surgery (CTS) patients. Cardiothoracic surgery patients with diabetes have improved clinical outcomes with maintained glycemic management, including improved hospital length of stay (LOS), surgical site infection risk, and rates of morbidity and mortality. A pharmacist-led insulin management service was implemented, granting pharmacists autonomy to adjust basal, bolus, and infusion insulin regimens to optimize glycemic management following CTS. Literature evaluating the impact on glycemic management in CTS patients following a pharmacist-led insulin management service is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The study objective was to compare postoperative glycemic management in CTS patients before and after implementation of a pharmacist-led insulin management service.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included adult CTS patients with diabetes with a hemoglobin A1c (HbA1c) of 6.5% or greater who received at least 2 basal insulin doses following postoperative intravenous (IV) insulin infusion. The primary outcome was the percentage of blood glucose concentrations within the target range (70–180 mg/dL) until postoperative Day 7 or discharge, if sooner. Secondary outcomes were average daily blood glucose, time to discontinuation of postoperative IV insulin infusion, incidence of hypoglycemia and hyperglycemia requiring re-initiation of an insulin infusion, hospital LOS, and postoperative surgical site infections within 3 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 200 patients were included, 100 in each group. Mean percent of glucose checks within target range was higher in the post-implementation group compared with the pre-implementation group (60.8 vs. 48.9, <i>p</i> = 0.0004). The post-implementation group achieved a lower mean daily blood glucose (170 vs. 191, <i>p</i> &lt; 0.0001) and spent fewer days on postoperative insulin infusion (1.24 vs. 1.85, <i>p</i> &lt; 0.0001). There were no differences in the incidence of hypoglycemia, re-initiation of insulin infusion, LOS, or surgical site infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Implementation of a pharmacist-led insulin management service was a safe and effective strategy to improve glycemic management in postoperative CTS patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"116-122"},"PeriodicalIF":1.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hemoglobin A1c reduction in Hispanic patients versus non-Hispanic patients with type 2 diabetes managed by a clinical pharmacist","authors":"Mayela Warner Pharm.D.,&nbsp;Ife Anachebe Pharm.D.,&nbsp;Samuel Newman M.S.,&nbsp;Somer Blair Ph.D.,&nbsp;Haley Leverett Pharm.D.","doi":"10.1002/jac5.70005","DOIUrl":"https://doi.org/10.1002/jac5.70005","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hispanic people are 1.6 times as likely to be diagnosed with type 2 diabetes mellitus (T2DM) as non-Hispanic White people. Clinical pharmacists can play a significant role in helping patients disproportionately affected by diabetes meet hemoglobin A1c (A1c) goals through medication management via collaborative practice agreements (CPAs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to evaluate A1c reduction in Hispanic and non-Hispanic patients with T2DM when managed by a clinical pharmacist utilizing a CPA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A single-center, retrospective, observational cohort study was conducted from August 30, 2019 to August 30, 2022. Patients were included if they were at least 18 years of age, diagnosed with T2DM, and had at least one office visit with a clinical pharmacist for diabetes management at John Peter Smith (JPS) Health Network. The study population was subdivided into two groups: Hispanic and non-Hispanic patients. The primary outcome was mean A1c reduction, defined as the difference in A1c at baseline and 12 months. Secondary outcomes included differences in variables for Hispanic patients who reached A1c goals versus those who did not.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data points were collected within 1 year from the first encounter with a clinical pharmacist. Three hundred patients were enrolled in the study, with 150 patients in each group. The mean A1c reduction in the Hispanic group was 1.6% (standard deviation [SD] = 2.654, 95% confidence interval [CI] [1.180–2.030]) and 2.0% (SD = 2.369, 95% CI [1.598–2.356]) in the non-Hispanic group (<i>p</i> = 0.20). There were no significant differences in variables for Hispanic patients who met A1c goals compared to Hispanic patients who did not achieve A1c goals. There was no significant difference in A1c reduction between Hispanic and non-Hispanic patients with T2DM who were managed by a clinical pharmacist utilizing a CPA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The findings from this study suggest that clinical pharmacist management of T2DM does not further contribute to the disparities experienced by Hispanic patients, but rather, it can serve as a valuable resource in their care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"205-213"},"PeriodicalIF":1.3,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening and treatment of iron deficiency among heart failure patients with impaired ejection fraction: The impact of a pharmacist-led protocol","authors":"Jamila Alaryani BSPharm,&nbsp;Yosef Manla M.D.,&nbsp;Emna Abidi Ph.D.,&nbsp;Obada Kholoki M.D.,&nbsp;Mohamed Hisham Pharm.D.,&nbsp;Firas Al Badarin M.D., M.Sc,&nbsp;Feras Bader M.D., M.S.,&nbsp;Bassam Atallah Pharm.D.","doi":"10.1002/jac5.2081","DOIUrl":"https://doi.org/10.1002/jac5.2081","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite guideline-recommended routine screening and iron deficiency (ID) treatment among heart failure (HF) patients, these practices are often underutilized. Currently, limited data are available on the outcomes of pharmacists' programs to enhance ID screening and management. Accordingly, we sought to describe the frequency and yield of screening for ID and intravenous (IV) iron replacement rates among our cohort of HF patients and examined the impact of implementing a pharmacist-led protocol (PLP) aimed at enhancing these rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective study involving HF patients with left ventricular ejection fraction (LVEF) &lt;45% at a quaternary care hospital in the Middle East/Gulf region. The PLP was introduced in August 2022. Data on demographics, comorbidities, echocardiographic parameters, laboratory findings (including ID screening and its findings), and rates of treatment with IV iron replacement were analyzed and compared between the pre-implementation group (<i>n</i> = 432, October 2015–February 2020) and the post-implementation group (<i>n</i> = 154, August 2022–January 2023).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Before the PLP, 63.2% (<i>n</i> = 273) of eligible patients underwent ID screening, with 80.6% (<i>n</i> = 220) found to have ID. Following the implementation of the PLP, screening rates significantly increased to 86.4% (<i>n</i> = 133) (<i>p</i> = 0.03), with 53.4% (<i>n</i> = 71) diagnosed with ID. The rate of IV iron replacement in ID patients improved from 30.4% (<i>n</i> = 67) in the pre-PLP group to 73% (<i>n</i> = 52) in the post-PLP group (<i>p</i> &lt; 0.001). Multivariable logistic regression identified baseline glomerular filtration rate (GFR) and hemoglobin levels as significant predictors of IV iron replacement in the pre-PLP cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Implementing a pharmacist-led protocol was significantly associated with enhancing the screening and treatment of ID in patients with HF and LVEF &lt;45%. This study demonstrates the crucial role of pharmacists in optimizing guideline-directed therapies, which can be replicated in various healthcare settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"182-191"},"PeriodicalIF":1.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}